Viewing data from:

RIFAMPIN

ANDA

RIFAMPIN | A090034 | LUPIN PHARMACEUTICALS INC

2 strengths0 unique patents0 unique exclusivities

Drug Pricing (NADAC)

National Average Drug Acquisition Cost — Week of 2026-07-15 | 6 NDCs

Highest NADAC/Unit

$0.6891

per ea

Lowest NADAC/Unit

$0.6179

per ea

Brand NDCs

Generic NDCs

NDC Description	NADAC/Unit	Unit	Type	Generic NADAC	Effective
00904731561RIFAMPIN 300 MG CAPSULE	$0.6891	EA	Generic	—	2026-06-17
60687058601RIFAMPIN 300 MG CAPSULE	$0.6891	EA	Generic	—	2026-06-17
68180065906RIFAMPIN 300 MG CAPSULE	$0.6891	EA	Generic	—	2026-06-17
68180065907RIFAMPIN 300 MG CAPSULE	$0.6891	EA	Generic	—	2026-06-17
60687057521RIFAMPIN 150 MG CAPSULE	$0.6179	EA	Generic	—	2026-06-17
68180065806RIFAMPIN 150 MG CAPSULE	$0.6179	EA	Generic	—	2026-06-17

Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.

API Supply Chain4 active DMFs5 inactive

4 active API suppliers hold Drug Master Files for this ingredient.

LUPIN LTDRIFAMPIN USP

DMF 132141998

EUROAPI ITALY SRLRIFAMPIN, USP

DMF 133831998

CKD BIO CORPRIFAMPIN

DMF 136631998

OLON SPARIFAMPIN

DMF 137961998

SYNTHO RIFA PVT LTDInactiveRIFAMPIN

DMF 76031988

SOLCHEM ITALIANA S P AInactiveRIFAMPIN

DMF 100271992

NOVARTIS PHARMACEUTICALS CORPInactiveRIFAMPIN

DMF 133981998

SICHUAN LONG MARCH PHARMACEUTICAL CO LTDInactiveRIFAMPIN

DMF 136441998

FERMIC SA DE CVInactiveRIFAMPIN

DMF 137171998

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (2)

Sort:

#001 — 150MG

0 patents0 exclusivities▴

CAPSULE;ORAL | Approved: Aug 21, 2013

No patent or exclusivity listings for this strength.

#002 — 300MG

0 patents0 exclusivities▾

CAPSULE;ORAL | Approved: Aug 21, 2013